noom semaglutide dosing expands its GLP-1 range with 'microdose' package Weight-loss company Noom pivots to

Following this spike, prescribing was relatively stable from September through November (0.01 percentage points per month), before increasing again from November to December (+0.04 points) and accelerating from December 2025 through February 2026 (+0.12 percentage points per month)

The magic is in their synergy

Well walk you through what liposuction actually does, who its right for, and what you can realistically expect before, during, and after the procedure

Zepbounds promising results position Eli Lilly as a solid competitor to Novo Nordisk in the obesity market, which has been dominated by Wegovy since its approval in 2021

Ann Nutr Metab 2004;48:296303 (DOI: 10.1159/000081076) Caloric restriction and intermittent fasting: Two potential diets for successful brain agingBronwen Martina, Corresponding author contact information, E-mail the corresponding author, Mark P

Higher-strength vials keep injection volumes practical